Your browser doesn't support javascript.
loading
It's a SMAD/SMAD World.
Taniguchi, Cullen; Maitra, Anirban.
Affiliation
  • Taniguchi C; Departments of Radiation Oncology, Experimental Radiation Oncology, and Cancer Biology, UT MD Anderson Cancer Center, Houston, TX, 77030, USA. Electronic address: ctaniguchi@mdanderson.org.
  • Maitra A; Departments of Pathology and Translational Molecular Pathology, UT MD Anderson Cancer Center, Houston, TX, 77030, USA.
Cell ; 161(6): 1245-6, 2015 Jun 04.
Article in En | MEDLINE | ID: mdl-26046433
ABSTRACT
DPC4/SMAD4 mutations are associated with aggressive pancreatic cancer. In this issue of Cell, Whittle et al. demonstrate that Runx3 expression combined with Dpc4/Smad4 status can predict the metastatic propensity of pancreatic tumors, providing valuable guidance for personalized therapy for patients with pancreatic cancer.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Pancreatic Neoplasms / Carcinoma, Pancreatic Ductal / Core Binding Factor Alpha 3 Subunit / Neoplasm Metastasis Type of study: Guideline / Prognostic_studies Limits: Animals / Humans Language: En Journal: Cell Year: 2015 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Pancreatic Neoplasms / Carcinoma, Pancreatic Ductal / Core Binding Factor Alpha 3 Subunit / Neoplasm Metastasis Type of study: Guideline / Prognostic_studies Limits: Animals / Humans Language: En Journal: Cell Year: 2015 Type: Article